<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002349</url>
  </required_header>
  <id_info>
    <org_study_id>TR-Med-NAR-Cluster</org_study_id>
    <nct_id>NCT04002349</nct_id>
  </id_info>
  <brief_title>Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis</brief_title>
  <official_title>Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Otolaryngology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In
      China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe
      economic and social burden, as well as the potential risk of developing other chronic
      diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to
      explore the classification and treatment strategies of chronic rhinitis in order to improve
      the health level of Chinese people.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relief of bothersome symptoms</measure>
    <time_frame>2 weeks</time_frame>
    <description>Determined by change of visual analog scale for symptoms</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Determination of the Efficacy of Different Medications for Idiopathic Rhinitis</condition>
  <condition>Impact of Different Medications on Biomarkers of Idiopathic Rhinitis</condition>
  <condition>Safety and Tolerance of Different Medications for Idiopathic Rhinitis</condition>
  <arm_group>
    <arm_group_label>A: Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treated by 0.9% Natural saline (NS) nasal spray: 2 sprays each side daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B: Budesonide Nasal Spray (Rhinocort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C: Levocabastine Nasal Spray (Livostine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated by Levocabastine(Livostinet, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D: Combined Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated by Budesonide Nasal Spray (Rhinocort, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.) nasal spray: 2 sprays each side daily in the morning and Levocabastine(Livostinet, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.) Nasal Spray: 2 sprays each side daily in the morning</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide Nasal Spray (Rhinocort, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.)</intervention_name>
    <description>Detailed in arm descriptions</description>
    <arm_group_label>B: Budesonide Nasal Spray (Rhinocort)</arm_group_label>
    <arm_group_label>D: Combined Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocabastine Nasal Spray (Livostine, Shanghai Johnson &amp; Johnson Pharmaceuticals, Ltd.)</intervention_name>
    <description>Detailed in arm descriptions</description>
    <arm_group_label>C: Levocabastine Nasal Spray (Livostine)</arm_group_label>
    <arm_group_label>D: Combined Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% natural saline</intervention_name>
    <description>Detailed in arm descriptions</description>
    <arm_group_label>A: Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Not younger than 18 years old

          -  Diagnosed as idiopathic rhinitis

          -  Signed and volunteered for the study

        Exclusion Criteria:

          -  Comorbid airway diseases including (but not limited to) upper airway infection,
             chronic rhinosinusitis, nasal polyps

          -  Allergic to the medicines about to study

          -  Having used oral glucocorticoids or antihistamine agents within 30 days of the
             enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luo Zhang, M.D.</last_name>
      <phone>(86)13910830399</phone>
      <email>dr.luozhang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luo Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yifan Meng</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yifan Meng, PhD</last_name>
      <phone>+8613581505557</phone>
      <email>mengyifan1015@126.com</email>
    </contact>
    <investigator>
      <last_name>Yifan Meng, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 27, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
    <mesh_term>Rhinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Levocabastine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

